TP53 and liver cancer: To validate this hypothesis in liver-specific deletion of Hpcal1 and established the clinical relevance between HPCAL1 and key driver genes of human HCC, we take advantage of hydrodynamic tail-vein injections to generate a MYC/Trp53-/- liver cancer model in which oncogenic MYC can be genomically integrated, and that TP53 is deficient to recapitulate the features of HCC, as previously described 34.